Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme
Free accessResearch articleFirst published online March, 2008
Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme
In subjects with impaired glucose tolerance (IGT) who participated in the Indian Diabetes Prevention Programme (IDPP), abnormalities related to body mass index, waist circumference (WC), blood pressure (BP), lipid profile and electrocardiography were analysed (at baseline and third-year follow-up) in control, lifestyle modification (LSM), metformin (MET) and LSM + MET groups.
At baseline, elevated levels of low-density lipoprotein cholesterol (LDL-C) showed the highest (78.6%) and total cholesterol (TC) showed the lowest (42%) prevalence. At follow-up, prevalence of hypertension (BP ≥ 130/≥.85 mmHg) had increased significantly in all groups. Cardiovascular abnormalities were lower in intervention groups, with the lowest rates in the MET group (p=0.013 vs. control); the LDL-C level decreased in intervention groups.
In this programme, Asian Indian IGT subjects were observed to have a high prevalence of cardiovascular risk factors. LSM and MET had beneficial effects on the atherogenic phenotype of lipids but had no influence on blood pressure.
1. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Program Research Group. N Engl J Med2002;346:393–403.
2.
2. Tuomilehto J, Lindstrom J, Eriksson JG et al. Finnish Diabetes Prevention Study group (DPS). Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med2001;344:1343–50.
3.
3. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmo feasibility study. Diabetologia1997;34:891–8.
4.
4. Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care1997;20:537–44.
5.
5. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP – 1). Diabetologia2006;49:289–97.
6.
6. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888–94.
7.
7. Lindstrom J, Louheranta A, Mannelin M et al. The Finnish Diabetes Prevention Study (DPS). Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care2003;26:3230–6.
8.
8. Ramachandran A, Snehalatha C, Kapur A et al. for the Diabetes Epidemiology Study Group in India (DESI). High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia2001;44:1094–101.
9.
9. Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Metabolic syndrome in urban Asian Indian adults – a population study using modified ATP III criteria. Diab Res Clin Pract2003;60:199–204.
10.
10. Yusuf S, Hewken S, Ounpuu S et al. INTERHEART study investigators. Obesity and the risk for myocardial infarction in 27, 000 participants from 52 countries: a case-control study. Lancet2005;366:1640–9.
11.
11. Laakso M, Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Review1997;5:294–315.
12.
12. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization, 1999.
13.
13. Expert Panel on Detection. Evaluation and Treatment of High Blood Cholesterol in Adults, Executive summary of the third report of the National Cholesterol Education Program (NCEP) of high blood cholesterol in adults (adult treatment panel III). JAMA2001;285:2486–97.
14.
14. Laakso M, Lehto S. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. Atherosclerosis1998;137:S65–S73.
15.
15. Rodriguez BL, Curb JD, Burchfiel CM et al. Impaired glucose tolerance, diabetes, and cardiovascular disease risk factor profiles in the elderly: the Honolulu Heart Program. Diabetes Care1996;19:587–90.
16.
16. Liao D, Shofer JB, Boyko EJ et al. Abnormal glucose tolerance and increased risk for cardiovascular disease in Japanese Americans with normal fasting glucose. Diabetes Care2001;24:39–44.
17.
17. Jiang R, Schulze MB, Li T et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care2004;27:1991–7.
18.
18. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapo B: the unappreciated atherogenic dyslipo-proteinemia in type 2 diabetes mellitus. Ann Intern Med2001;18:447–59.
19.
19. Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians – Results of Indian Diabetes Prevention Programme. Diabetes Res Clin Pract2007;76:215–18.
20.
20. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. For the STOP-NIDDM Trial Research group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM Trial. JAMA2003;290:486–94.
